{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-25-000007","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.785691+00:00","generated_at":"2026-05-27T22:34:06.436021+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months","bullets":["1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.","Durable disease control ≥180 days observed in 46.2% of treated patients.","Grade ≥3 TEAEs in 30.8% of patients; most AEs mild to moderate.","Expansion cohort enrolling up to 50 patients, data expected Q3 2025.","Two PRs occurred in patients who had failed prior FOLFIRI-based therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-25-000007","json":"https://secwatch.observer/filing/0002007919-25-000007.json","markdown":"https://secwatch.observer/filing/0002007919-25-000007.md","text":"https://secwatch.observer/filing/0002007919-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/0002007919-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/inhibrx-20250121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:34:06.436021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}